Searched for
RESPIRATORY TREATMENT PORTFOLIO
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Wealth creation is also about ignoring noise on the street: 15 mid- and small-cap stocks from different sectors which fit the billIn the April 2022-September 2024 bull market, every management appeared capable. Margins expanded, working capital looked manageable, capit...
- Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...
- Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosolPharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...
- Glenmark’s nasal spray Ryaltris gets China’s NMPA nod for allergic rhinitis; to be commercialised by Grand PharmaRyaltris is a fixed-dose combination of olopatadine, an antihistamine and mometasone furoate, a corticosteroid to treat the symptoms of all...
- Verona Pharma stock jumps 20% on $10B Merck deal—can FDA-approved Ohtuvayre reshape COPD care?Verona Pharma stock jumped 20% after Merck announced it will acquire the British biotech in a $10 billion deal. Merck will pay $107 per sha...
- GSK boosts respiratory portfolio with $1.4 bn Aiolos Bio dealGSK will pay $1 billion upfront and up to $400 million in certain success-based regulatory milestone payments. It will also make milestone ...
- AstraZeneca to open 5 asthma clinics in IndiaThe centers will serve as a hub for the treatment and management of severe asthma patients, and support evolving severe asthma centres for ...
- Lupin inks pact to acquire two inhalation brands from Sunovion for USD 75 mnThe acquisition of these two brands will expand the company's inhalation product portfolio in the US and strengthen its presence in the res...
- Themis Medi bets big on antiviral drug for CovidThemis had launched inosine pranobex under brand name Viralex in June this year. Despite the drug not figuring in the government's Covid tr...
- Mankind Pharma to acquire Combihale and Daffy brands from Dr Reddy's LaboratoriesMankind Pharma said the market for Combihale is valued at Rs 900 crore growing at 14 per cent. The acquisition of the product is expected t...
- Glenmark arm gets Russian health ministry nod for nasal spray RyaltrisIn Russia, allergic rhinitis affects 10-20 per cent of the population on average, with certain regions having a higher prevalence rate of 1...
- Novartis signs $50 million deal for Mesoblast cell therapy for COVID and beyondThe Swiss drugmaker's deal with Australia-based Mesoblast secures rights to develop, commercialize and manufacture Remestemcel-L for treati...
- Cipla hits 15% upper circuit as USFDA gives final approval to Albuterol Inhalation AerosolFollowing the development, the scrip hit its 15 per cent upper circuit limit at Rs 589.95.
- Cipla gets final approval from USFDA for Albuterol Sulfate Inhalation AerosolIn a regulatory filing the company said "it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfa...
- FDA okays Glenmark's first-in-human study for respiratory drugAccording to IMS sales data for the 12-month period ending February 2017, annual sales of XOLAIR 150 mg injection was approximately $1.7 bi...
Load More
